Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT

J. Sanz, M. Labopin, D. Blaise, AM. Raiola, A. Busca, J. Vydra, J. Tischer, P. Chevallier, S. Bramanti, R. Fanin, G. Socié, E. Forcade, N. Kröger, Y. Koc, M. Itäla-Remes, M. Zecca, A. Nagler, E. Brissot, A. Spyridonidis, A. Bazarbachi, S. Giebel,...

. 2024 ; 8 (10) : 2332-2341. [pub] 20240528

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013858

There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.

Azienda Ospedaliero Universitaria di Udine Udine Italy

Blood and Marrow Transplant Unit Saint Louis Hospital Paris France

Bone Marrow Transplantation Program Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon

CIBERONC Carlos 3 Health Institute Madrid Spain

Departament de Medicina Universitat de València València Espanya

Department of Bone Marrow Transplantation and Oncohematology Maria Sklodowska Curie National Research Institute of Oncology Gliwice Poland

Department of Hematology and Cellular Therapy CHU Bordeaux Bordeaux France

Department of Internal Medicine Bone Marrow Transplantation Unit University Hospital of Patras Patras Greece

Division of Hematology and Bone Marrow Transplantation Chaim Sheba Medical Center Ramat Gan Israel

EBMT Paris Office Hospital Saint Antoine Paris France

Grosshadern Clinic Munich Germany

Hematology and Bone Marrow Transplant Unit San Raffaele Scientific Institute IRCCS Milano Italy

Hematology Department La Fe University and Polytechnic Hospital Valencia Spain

Hospital Saint Antoine Sorbonne University Paris France

Humanitas Research Hospital Milano Italy

Institute of Hematology and Blood Transfusion Prague Czech Republic

IRCCS Ospedale Policlinico San Martino Genova Italy

Medicana International Hospital Istanbul Istanbul Turkey

Pediatric Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy

S S Trapianto di Cellule Staminali Torino Italy

Transplantation and Cellular Therapy Program Marseille France

Turku University Hospital Turku Finland

University Hospital Eppendorf Hamburg Germany

University Hospital of Nantes Nantes France

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013858
003      
CZ-PrNML
005      
20240905134332.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2023012133 $2 doi
035    __
$a (PubMed)38429091
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sanz, Jaime $u Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain $u CIBERONC, Carlos III Health Institute, Madrid, Spain $u Departament de Medicina, Universitat de València, València, Espanya $1 https://orcid.org/0000000169344619
245    10
$a Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT / $c J. Sanz, M. Labopin, D. Blaise, AM. Raiola, A. Busca, J. Vydra, J. Tischer, P. Chevallier, S. Bramanti, R. Fanin, G. Socié, E. Forcade, N. Kröger, Y. Koc, M. Itäla-Remes, M. Zecca, A. Nagler, E. Brissot, A. Spyridonidis, A. Bazarbachi, S. Giebel, S. Piemontese, M. Mohty, F. Ciceri
520    9_
$a There is a paucity of information to guide the selection of the most suitable donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we conducted a retrospective analysis to evaluate the impact of Haplo donor characteristics on outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with posttransplant cyclophosphamide (PTCy). The primary end point was graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS). Overall, 2200 patients were included. The median age of donors was 37 years (range, 8-71); 820 (37%) were females, including 458 (21%) who were used for male recipients. In addition, 1631 donors (74%) donated peripheral blood (PB). Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. The use of PB, older donors' ages (>37 years), and female donors to male recipients negatively affected GRFS. Donor's age and female donor-to-male recipient combination also affected nonrelapse mortality, leukemia-free survival, and overall survival. In conclusion, donor-related variables significantly influence outcomes in patients with AML after Haplo-HSCT with PTCy. When possible, younger donors and male donors for male recipients should be prioritized. The use of bone marrow can additionally prevent GVHD.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladiství $7 D000293
650    12
$a transplantace hematopoetických kmenových buněk $x metody $x škodlivé účinky $7 D018380
650    _2
$a senioři $7 D000368
650    12
$a nemoc štěpu proti hostiteli $x etiologie $x prevence a kontrola $7 D006086
650    _2
$a dítě $7 D002648
650    _2
$a mladý dospělý $7 D055815
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a haploidentická transplantace $x metody $7 D000075442
650    _2
$a dárci tkání $7 D014019
650    _2
$a výběr dárců $7 D046148
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u EBMT Paris Office, Hospital Saint Antoine, Paris, France
700    1_
$a Blaise, Didier $u Transplantation and Cellular Therapy Program, Marseille, France $1 https://orcid.org/0000000256849447
700    1_
$a Raiola, Anna Maria $u IRCCS Ospedale Policlinico San Martino, Genova, Italy
700    1_
$a Busca, Alessandro $u S.S. Trapianto di Cellule Staminali, Torino, Italy
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Tischer, Johanna $u Grosshadern Clinic, Munich, Germany
700    1_
$a Chevallier, Patrice $u University Hospital of Nantes, Nantes, France
700    1_
$a Bramanti, Stefania $u Humanitas Research Hospital, Milano, Italy $1 https://orcid.org/0000000241177991
700    1_
$a Fanin, Renato $u Azienda Ospedaliero Universitaria di Udine, Udine, Italy
700    1_
$a Socié, Gérard $u Blood and Marrow Transplant Unit, Saint-Louis Hospital, Paris, France
700    1_
$a Forcade, Edouard $u Department of Hematology and Cellular Therapy, CHU Bordeaux, Bordeaux, France
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
700    1_
$a Koc, Yener $u Medicana International Hospital Istanbul, Istanbul, Turkey
700    1_
$a Itäla-Remes, Maija $u Turku University Hospital, Turku, Finland $1 https://orcid.org/0000000158441632
700    1_
$a Zecca, Marco $u Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy $1 https://orcid.org/0000000288181744
700    1_
$a Nagler, Arnon $u Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat-Gan, Israel
700    1_
$a Brissot, Eolia $u Hospital Saint Antoine, Sorbonne University, Paris, France
700    1_
$a Spyridonidis, Alexandros $u Department of Internal Medicine, Bone Marrow Transplantation Unit, University Hospital of Patras, Patras, Greece $1 https://orcid.org/0000000330972532
700    1_
$a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
700    1_
$a Giebel, Sebastian $u Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland $1 https://orcid.org/0000000248274401
700    1_
$a Piemontese, Simona $u Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy
700    1_
$a Mohty, Mohamad $u Hospital Saint Antoine, Sorbonne University, Paris, France
700    1_
$a Ciceri, Fabio $u Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, Milano, Italy
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 10 (2024), s. 2332-2341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38429091 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134326 $b ABA008
999    __
$a ok $b bmc $g 2143582 $s 1225724
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 10 $d 2332-2341 $e 20240528 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace